Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Biosimilars Guidances Address Immunogenicity Studies, European Bridge Data, Analytics

Executive Summary

The agency’s first three draft guidances on biosimilar product development describe how to characterize biosimilar and reference products and extrapolate data on one condition of use to another. FDA says interchangeability is difficult to determine now and will require a switching study.

You may also be interested in...



Sandoz’s Biosimilar Data-Bridging Plans For Zarxio Faced FDA Doubts

FDA 'strongly encouraged' Sandoz to conduct three-way clinical PK/PD study comparing its Zarxio biosimilar to the EU- and U.S.-approved versions of Amgen’s Neupogen; however, the firm succeeded in using only analytical data to justify relevance of studies using the European reference product.

Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny

PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.

Biosimilars: FDA’s Four-Tiered Assessment Draws Industry Scrutiny

PhRMA asks FDA to remove the categorization of a product as not similar, similar, highly similar, or similar with fingerprint-like similarity.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054183

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel